Cullinan Therapeutics Receives FDA Orphan Drug Designation
Cullinan Therapeutics has received FDA Orphan Drug Designation for CLN-049, a novel FLT3xCD3 T cell engager, for treating relapsed/refractory acute myeloid leukemia (AML). This designation highlights the urgent need for new therapies in AML, especially for patients with TP53-mutated AML who face poor prognoses. CLN-049 is designed to target FLT3-expressing leukemia cells regardless of mutational status and is currently undergoing Phase 1 clinical trials.
Stifel reiterates Cullinan Oncology stock rating on trial data
Stifel maintained a Buy rating and a $28.00 price target for Cullinan Oncology Inc. after previewing abstract data for its CLN-978 trial. Initial results for systemic lupus erythematosus and rheumatoid arthritis patients showed only mild side effects and suggest a competitive product profile, with more comprehensive data expected in June 2026. This positive outlook, coupled with other recent favorable analyst ratings and an Orphan Drug Designation for CLN-049, indicates continued confidence in Cullinan's pipeline and strategic direction.
FDA grants orphan drug status to Cullinan’s CLN-049 for AML
Cullinan Therapeutics (NASDAQ:CGEM) has been granted Orphan Drug Designation by the FDA for CLN-049, its investigational treatment for relapsed/refractory acute myeloid leukemia (AML). This designation provides incentives such as tax credits and potential market exclusivity. The drug is currently in Phase 1 trials and previously received Fast Track designation for the same condition.
FDA grants orphan status to CLN-049 for relapsed or refractory AML patients
Cullinan Therapeutics announced that the FDA granted Orphan Drug Designation to CLN-049, a novel FLT3xCD3 T cell engager, for treating relapsed/refractory acute myeloid leukemia (AML). This designation recognizes the urgent unmet need for new therapies in AML patients, especially those with TP53-mutated disease, and follows promising Phase 1 clinical trial results for CLN-049. Despite the positive regulatory news, Cullinan Therapeutics' stock (CGEM) declined, indicating a notable negative market reaction.
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics announced it will present initial clinical data for CLN-978, a subcutaneously administered CD19xCD3 T cell engager, at the EULAR 2026 Congress. The data from two Phase 1 studies (OUTRACE RA and OUTRACE SLE) showed a favorable safety profile, robust B cell depletion, and early signals of promising clinical activity in patients with rheumatoid arthritis and systemic lupus erythematosus. CLN-978 is a wholly owned asset with potential as a convenient, off-the-shelf therapeutic option for autoimmune diseases.
Alzheimer's and cancer: 10 trial drugs trace back to one antibody lab
MindWalk Holdings Corp. announced that over 20 partner-owned drug programs, originating from their antibody discovery work, have reached clinical trials, with ten currently in active Phase 1-3 trials for conditions like oncology, immunology, neurology, and infectious diseases. The company highlights its proprietary HYFT® biological intelligence infrastructure and B cell Llama™ camelid nanobody discovery platform as key drivers behind these successes, emphasizing the integration of AI with their wet-lab capabilities. Featured clinical-stage programs include ANX005 for Guilláin-Barré Syndrome and PMN310 for Alzheimer’s disease.
Cullinan trial drug depletes B cells in refractory arthritis and lupus
Cullinan Therapeutics will present initial Phase 1 clinical data for its subcutaneous CD19xCD3 T cell engager, CLN-978, at the EULAR 2026 Congress. The data from OUTRACE RA and OUTRACE SLE studies in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus show favorable safety, robust B cell depletion, and early signals of clinical activity. Updated data, including additional patients, will be shared in a poster session on June 6, 2026.
(CGEM) Movement Within Algorithmic Entry Frameworks
The article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using algorithmic entry frameworks. It highlights a weak near-term sentiment but strong mid and long-term outlook, with an exceptional 65.0:1 risk-reward setup targeting an 18.4% gain. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis indicating support and resistance levels.
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan Therapeutics announced its first-quarter 2026 financial results and provided a comprehensive corporate update. Key highlights include upcoming presentations of initial clinical data for CLN-978 in SLE and RA at the EULAR 2026 Congress in June, FDA acceptance of the zipalertinib NDA for EGFR ex20ins NSCLC with a PDUFA target date of February 27, 2027, and a strong cash position of $393.3 million extending into 2029. The company is advancing multiple clinical programs in both immunology and oncology, with several significant milestones anticipated throughout 2026.
Cullinan Therapeutics (CGEM) logs Q1 loss as FDA accepts zipalertinib NDA and cash tops $351.9M
Cullinan Therapeutics (CGEM) reported a Q1 2026 net loss of $49.661 million, driven by significant investment in its autoimmune and oncology programs. Despite the loss, the company's financial position remains strong with $351.9 million in cash, cash equivalents, and short-term investments, expected to fund operations for at least twelve months. Key developments include the FDA's acceptance of a new drug application for zipalertinib in NSCLC, with a target action date of February 27, 2027, and the completion of enrollment for a Phase 3 trial of the same drug.
Cullinan Therapeutics (CGEM) posts Q1 loss, advances autoimmune and cancer pipeline
Cullinan Therapeutics reported a Q1 2026 net loss of $49.7 million, with cash reserves of $393.3 million, expected to fund operations into 2029. The company highlighted significant pipeline progress, including the FDA's acceptance of the zipalertinib NDA for EGFR ex20ins NSCLC with a PDUFA date in February 2027, and upcoming data readouts for multiple T cell engager programs in autoimmune diseases and oncology. Despite ongoing losses, the company maintains a strong financial position and anticipates several clinical and regulatory milestones in 2026 and 2027.
Cullinan Therapeutics (NASDAQ: CGEM) CSO sells 8,000 shares, exercises 4,000 options
Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction involving 8,000 shares of Common Stock at weighted average prices of $14.60 and $15.58. Concurrently, she exercised stock options for 4,000 shares at $4.30 each. These transactions were performed under a pre-established Rule 10b5-1 trading plan dated August 7, 2025.
How (CGEM) Movements Inform Risk Allocation Models
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models, highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents exceptional risk-reward short setups and outlines three distinct trading strategies: a Position Trading Strategy (LONG), a Momentum Breakout Strategy (BREAKOUT), and a Risk Hedging Strategy (SHORT). The analysis provides entry zones, targets, and stop losses based on multi-timeframe signal analysis.
Cullinan Therapeutics (CGEM) outlines 2026 virtual annual meeting
Cullinan Therapeutics (CGEM) has announced its 2026 virtual annual meeting for June 16, 2026, where stockholders will vote on re-electing two Class III directors, ratifying KPMG LLP as the independent auditor, and approving executive compensation. The meeting will address key corporate governance matters, including director appointments, financial oversight, and executive pay packages. Key figures such as CEO Nadim Ahmed's 2025 compensation and the company's shares outstanding are detailed.
FDA starts review of new lung cancer drug, decision due Feb. 2027
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib, a drug developed by Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The decision date for approval is set for February 27, 2027. This submission is supported by positive data from the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients.
Cullinan Therapeutics' NDA For Zipalertinib Accepted By FDA
The FDA has accepted Cullinan Therapeutics' New Drug Application for zipalertinib to treat non-small cell lung cancer with EGFR exon 20 insertion mutations, setting a PDUFA target action date of February 27, 2027. This application is supported by positive Phase 2b data from the REZILIENT1 trial, which demonstrated a strong objective response rate. Following the announcement, Cullinan Therapeutics' shares saw a gain of over 2% in pre-market trading.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) has received a consensus "Moderate Buy" recommendation from analysts, with an average one-year price target of $29.56, suggesting significant upside from its current share price of $15.21. The biopharmaceutical company recently reported better-than-expected earnings and is advancing multiple Phase I oncology programs. While institutional investors hold a large portion of the shares, insiders have been net sellers over the past 90 days.
How Cullinan Oncology Inc. (CGEM) Affects Rotational Strategy Timing
The article analyzes Cullinan Oncology Inc. (CGEM) using AI models, indicating strong sentiment across all time horizons. It provides institutional trading strategies including position trading (long), momentum breakout, and risk hedging (short), along with multi-timeframe signal analysis. The analysis identifies key support and resistance levels for CGEM, suggesting specific entry and exit points for various trading approaches.
CGEM SEC Filings - Cullinan Oncology Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Cullinan Oncology (CGEM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It highlights key events such as clinical data updates for CLN-049 and CLN-978, financial results, and corporate actions. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents to assist investors in analyzing CGEM's progress and strategic direction.
CGEM SEC Filings - Cullinan Oncology Inc 10-K, 10-Q, 8-K Forms
This page provides access to Cullinan Oncology Inc.'s (CGEM) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing financial results, clinical trial updates for pipeline assets like CLN-049 and CLN-978, and corporate actions such as the discontinuation of certain programs. The platform also offers AI-powered summaries and impact analysis for easier interpretation of these regulatory documents.
CGEM SEC Filings - Cullinan Oncology Inc 10-K, 10-Q, 8-K Forms
This page provides access to Cullinan Oncology Inc. (CGEM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, with AI-powered summaries. Recent filings include details on executive stock option grants and sales, and significant ownership disclosures by investment groups. The platform aims to offer comprehensive data for investors tracking CGEM's biopharmaceutical developments and corporate actions.
(CGEM) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting a mid-channel oscillation pattern and a strong risk-reward setup. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis. The report identifies positive near-term sentiment while noting a weak mid-term bias within a long-term strength context.
Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation
Clear Street reiterated a Buy rating and a $777.00 price target for Cullinan Oncology (NASDAQ:CGEM) after Gilead Sciences' acquisition of Ouro Medicines. This acquisition validates Cullinan's velinotamig, which uses a similar BCMA x CD3 mechanism, and other clinical programs. The company has several data readouts expected in 2026 for its autoimmune and oncology programs, and analysts like Stifel and Guggenheim have also set Buy ratings with price targets of $28 and $30 respectively.
Responsive Playbooks and the CGEM Inflection
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), noting a weak near and mid-term sentiment despite a positive long-term outlook. It identifies an exceptional short setup due to a mid-channel oscillation pattern, offering a significant risk-reward ratio. The report provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis.
Cullinan lines up 2026 lupus and cancer trial results with $439M cash
Cullinan Therapeutics reported Q4 and full-year 2025 financial results, showing $439.0 million in cash, cash equivalents, investments, and interest receivable, providing a runway into 2029. The company outlined its 2026 clinical and regulatory roadmap, including initial data for CLN-978 in SLE and RA in Q2 2026, repeat-dosing RA data in Q3 2026, and the completion of zipalertinib's rolling NDA submission and REZILIENT3 enrollment with top-line results expected by year-end 2026. Despite a moderate negative market reaction to the news, the company emphasizes the potential of its T cell engager programs and upcoming milestones.
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics announced its financial results for Q4 and full year 2025, with cash and investments totaling $439.0 million, providing a runway into 2029. The company highlighted significant progress in its clinical pipeline, including initial clinical data for CLN-978 in autoimmune diseases expected in Q2 2026 and the completion of the rolling NDA submission for zipalertinib. Cullinan is advancing its oncology portfolio with CLN-049 and zipalertinib, aiming for multiple regulatory and clinical milestones in 2026.
Stifel raises Cullinan Oncology stock price target on autoimmune progress
Stifel increased its price target for Cullinan Oncology Inc. (NASDAQ:CGEM) to $28 from $22, maintaining a Buy rating, due to the biotech company's progress in B-cell driven autoimmune diseases. The firm highlighted Cullinan's strong financial position with more cash than debt and upcoming data readouts for its clinical programs in 2026 for systemic lupus erythematosus, rheumatoid arthritis, and Sjogren’s disease, which are key catalysts for investor interest. The stock has seen a significant 137% return over the past six months, reflecting growing appreciation for T-cell engagers in future B-cell treatment paradigms.
Cullinan Therapeutics 10-K — $0 Revenue, Net Loss $219.9M
Cullinan Therapeutics reported no product revenue and a net loss of $219.9 million for the year, indicating a focus on clinical-stage investment over commercial sales. The company's operations resulted in a $241.6 million loss due to operating expenses. Despite ongoing losses, Cullinan Therapeutics is advancing multiple clinical programs and expects its cash resources to fund operations into 2029.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Cullinan Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, at 10:00 a.m. ET. A webcast of the event will be available on the company's investor relations website. Cullinan Therapeutics focuses on developing high-impact therapies for autoimmune diseases and cancer, leveraging expertise in T cell engagers.
Cullinan Therapeutics (Nasdaq: CGEM) details 2025 loss and cash runway into 2029
Cullinan Therapeutics reported a net loss of $219.9 million for 2025, an increase from $167.4 million in 2024, primarily due to higher research and development expenses. Despite the loss, the company holds $439.0 million in cash, equivalents, and investments as of December 31, 2025, which it projects will fund operations into 2029. Cullinan also outlined several key milestones for 2026 across its pipeline, including initial clinical data for CLN-978 in autoimmune diseases and advancement of CLN-049 towards registrational development in AML.
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics announced its fourth quarter and full year 2025 financial results, alongside a corporate update detailing significant progress in its clinical programs. Key milestones include upcoming data releases for CLN-978 in autoimmune diseases, the completion of a rolling NDA submission for zipalertinib, and the full enrollment of the REZILIENT3 frontline study. The company reported $439.0 million in cash and investments as of December 31, 2025, providing a financial runway into 2029.
[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%)
Kynam Capital group has disclosed a passive investment in Cullinan Therapeutics, Inc. (CGEM), beneficially owning 3,114,132 shares, which represents 5.27% of the common stock as of December 31, 2025. The filing, a SCHEDULE 13G, indicates shared voting and dispositive power among Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. This disclosure is for regulatory tracking and does not indicate any intent to influence control of the issuer.
Cullinan Therapeutics (CGEM) CSO sells 1,780 shares in Rule 10b5-1 trade
Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics (CGEM), sold 1,780 shares of common stock at a weighted average price of $14.14 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on August 7, 2025. Following the sale, Michaelson directly holds 174,844 shares of Cullinan Therapeutics common stock.
CGEM Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Cullinan Oncology Inc (CGEM), presenting its income statement, balance sheet, cash flow statement, and key financial ratios derived from SEC filings. The analysis highlights that CGEM is not profitable, with negative net income and EBITDA in fiscal year 2024, a low Piotroski F-Score indicating weak financial health, and low-quality earnings primarily driven by accounting accruals. The company also faces a limited cash runway of approximately 7 months based on its operating cash burn.
Clinical-stage biopharma Cullinan CEO, CMO set for March investor chats
Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in two upcoming investor conferences in early March 2026. They are scheduled to present at the TD Cowen 46th Annual Healthcare Conference on March 3 and the Leerink Global Healthcare Conference on March 10. Webcasts of these fireside chats will be available on the company's investor relations website.
The Technical Signals Behind (CGEM) That Institutions Follow
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models, highlighting strong sentiment across all time horizons supporting an overweight bias despite elevated downside risk and no clear price positioning signal. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss points. The analysis includes multi-timeframe signal strengths and support/resistance levels generated by AI for informed trading decisions.
BVF group discloses 9.99% Cullinan Therapeutics (CGEM) ownership via 13G/A
BVF group has filed an amended Schedule 13G disclosing a 9.99% passive stake in Cullinan Therapeutics (CGEM). As of December 31, 2025, BVF entities and a managed account beneficially owned 5,918,481 common shares, which includes shares convertible from Series A preferred stock, subject to a 9.99% "Conversion Blocker." The filing asserts that the investment is passive and not intended to influence control of Cullinan Therapeutics.
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near
Cullinan Therapeutics executives have identified 2026 as a "defining year" due to anticipated catalysts from their T-cell engager programs, CLN-978 and CLN-049, and updates on their partnered EGFR exon 20 inhibitor, zipalertinib. The company reported over $430 million in cash, providing runway into 2029, and is pushing for first-in-class or best-in-class therapies in oncology and autoimmune diseases. Key developments include promising early AML activity for CLN‑049, advancing CLN‑978 for autoimmune diseases, and Taiho's near-complete rolling NDA submission for zipalertinib.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Cullinan Therapeutics, Inc. announced that its CEO, Nadim Ahmed, and CMO, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026. The biopharmaceutical company focuses on developing therapies for autoimmune diseases and cancer. A webcast of the chat will be available on the company's investor relations website.
Cullinan leaders join Citi virtual oncology fireside chat on Feb. 19
Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, at 10:00 a.m. ET. A live webcast of the discussion will be available on the company's investor relations website. This event is part of Cullinan's ongoing investor relations efforts, following recent milestones such as regulatory designations, positive clinical data, and a strong cash position.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, at 10:00 a.m. ET. The clinical-stage biopharmaceutical company focuses on developing therapies for autoimmune diseases and cancer. A webcast of their discussion will be available on the company's investor relations website.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit. The event is scheduled for Thursday, February 19, 2026, at 10:00 a.m. ET. A webcast will be available on the company's investor relations website for those interested.
Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum
Cullinan Therapeutics (NASDAQ: CGEM) anticipates a catalyst-rich 2026, driven by key advancements in its CLN-978 and CLN-049 programs. The company expects Q2 data for CLN-978, a T-cell engager for lupus and rheumatoid arthritis, focusing on B-cell depletion and safety. Additionally, CLN-049 for AML received FDA Fast Track designation, with plans for dose expansion and a Phase II study targeting 2027, supported by a strong cash position of over $430 million into 2029.
Precision Trading with Cullinan Oncology Inc. (CGEM) Risk Zones
This article provides an analysis of Cullinan Oncology Inc. (CGEM) stock with a focus on risk zones and trading strategies. It highlights a weak near-term sentiment but potential long-term strength, offering institutional trading strategies for different risk profiles. The analysis includes multi-timeframe signal analysis and AI-generated signals for real-time insights for investors.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target By Investing.com
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30.00 price target, predicting a significant upside. The firm sees the current stock price as an attractive entry point, anticipating important Phase 1 data catalysts for the company's T-cell engagers in autoimmune diseases and AML throughout 2024. Cullinan's CLN-978 is highlighted as a key value driver, with upcoming data readouts in various autoimmune conditions, and another drug, CLN-049, has received Fast Track designation from the FDA for AML.
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Exploring a Promising 148.86% Upside in Biotech
Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company, is generating significant investor interest due to an estimated 148.86% potential upside, according to recent analyst ratings. Despite currently reporting losses and negative free cash flow characteristic of a developmental biotech, the company's strong pipeline, strategic collaborations, and positive analyst sentiment point towards a high-risk, high-reward investment opportunity in innovative therapies for autoimmune diseases and cancer. Technical indicators also suggest the stock is in oversold territory, which could appeal to long-term investors.
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
Cullinan Therapeutics, a clinical-stage biopharmaceutical company focusing on autoimmune diseases and cancer, announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat. This event will take place at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 11:00 a.m. ET. A webcast of the chat will be available on the company's investor relations website.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30 price target, citing a potential 151% upside. The firm sees this as a good entry point before upcoming Phase 1 data catalysts for the company's T-cell engagers in autoimmune diseases and AML in 2024. Cullinan's strong recent performance, with a 56% price return over the last six months, and the identification of CLN-978 as a primary value driver underpin this positive outlook.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target By Investing.com
Guggenheim has initiated coverage on Cullinan Oncology (NASDAQ:CGEM) with a Buy rating and a $30 price target, citing a "good entry point" ahead of anticipated Phase 1 data catalysts for its T-cell engagers. The firm highlights CLN-978 as a primary value driver, expecting data from dose escalations in autoimmune diseases later in 2024. Despite competitive risks, the analyst's outlook is supported by CGEM's recent strong performance and upcoming clinical milestones.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30 price target, predicting a 151% upside. The firm sees this as a good entry point before upcoming Phase 1 data releases for T-cell engagers in autoimmune diseases and AML throughout 2024, with CLN-978 identified as a key value driver. This positive outlook is supported by recent strong performance and other promising clinical developments for the company's therapeutic candidates.
